Prognostic factors in patients with advanced neuroendocrine neoplasia treated with radiopeptides (PRRT) – Data from the national registry SEPTRALU

#3781

Introduction: PRRT is established in the treatment repertoire for advanced neuroendocrine neoplasms (NEN) expressing somatostatin receptors, without strong evidence for other factors influencing their activity.

Aim(s): To analyse prognostic factors in patients with an advanced NEN treated with 177Lu-DOTATATE.

Materials and methods: SEPTRALU (NCT04949282) is a national registry of NENs treated with PRRT. To specify the multivariable models, the “rule of thumb” of having at least 15 events per degree of freedom spent was applied.

Conference:

Presenting Author:

Authors: Bello P, Mitjavila Casanovas M, Jimenez-Fonseca P, Cabezas Agrícola J, Hernando Cubero J,

Keywords: 177Lu-DOTATATE, neuroendocrine tumor, PRRT, prognosis, radionuclide therapy, survival,